BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT

Rhea-AI Summary

Bioxytran (OTC: BIXT) completed a private placement on March 18, 2026, raising approximately $1.2 million. The company issued about 21,071,667 common shares at ~$0.055 per share and warrants to buy up to 19,750,001 shares at $0.12, five-year term.

The company said it will use net proceeds for working capital, development programs, and selected commercialization, including an A-SUQAR® dietary supplement launch expected this quarter.

Positive

• $1.2M financing strengthens company liquidity
• 21,071,667 shares issued provides immediate capital
• Warrants for 19,750,001 shares offer potential future capital
• Proceeds earmarked for development programs and commercialization
• Near-term commercial push: A-SUQAR® launch expected this quarter

Negative

• Issuance of 21,071,667 shares causes equity dilution
• Up to 19,750,001 warrant shares may further dilute on exercise
• Securities unregistered; resale restrictions limit liquidity

Financing strengthens balance sheet and supports advancement of key development initiatives

NEWTON, MA, March 20, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology company focused on developing therapies targeting hypoxia and viral diseases, today announced that it has completed a private placement financing on March 18, 2026, resulting in gross proceeds of approximately $1.2 million.

In connection with the financing, the Company issued an aggregate of approximately 21,071,667 shares of its common stock at a purchase price of approximately $0.055 per share. Investors also received warrants to purchase up to 19,750,001 additional shares of common stock at an exercise price of $0.12 per share. The warrants have a term of five years from the date of issuance.

The securities were offered and sold in a private placement pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Regulation D promulgated thereunder. The securities have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

The Company intends to use the net proceeds from the financing for working capital and general corporate purposes, including advancing its development programs and supporting selected commercialization initiatives.

“This financing strengthens our balance sheet and supports the advancement of our clinical and development initiatives,” said David Platt, PhD, Chief Executive Officer of Bioxytran. “In parallel, we are beginning to translate our galectin-targeting platform into commercial opportunities, including the market introduction of A-SUQAR^®, our plant-derived dietary supplement expected to launch this quarter. This dual-track approach allows us to pursue near-term commercialization while continuing to advance our higher-value pharmaceutical programs.”

The warrants issued in connection with the financing provide the potential for additional capital upon exercise, further supporting the Company’s long-term growth plans.

About Bioxytran, Inc.

Bioxytran, Inc. is a biotechnology company focused on the development of therapeutics targeting hypoxia-related conditions and galectin-targeting carbohydrate technologies, with applications across infectious viral diseases, metabolic health, and inflammation. The company leverages proprietary technologies to address significant unmet medical needs, with programs spanning pharmaceutical development and select commercial applications.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the use of proceeds, future development plans, anticipated commercialization activities, and potential warrant exercises. Actual results may differ materially from those projected due to various factors. Bioxytran undertakes no obligation to update these statements except as required by law.

For more information, please visit:
www.bioxytraninc.com

Investor Contact:
David Platt, PhD
CEO, Bioxytran, Inc.
617-484-1199
David.Platt@bioxytraninc.com

FAQ

How much did Bioxytran (BIXT) raise in the March 18, 2026 private placement?

Bioxytran raised approximately $1.2 million in gross proceeds. According to the company, the financing closed March 18, 2026, and the net proceeds will support working capital, development programs, and selected commercialization initiatives.

How many shares and what price did Bioxytran (BIXT) issue in the March 2026 financing?

The company issued about 21,071,667 common shares at approximately $0.055 per share. According to the company, these shares were sold in a private placement exempt from registration under Section 4(a)(2)/Regulation D.

What are the terms of the warrants issued by Bioxytran (BIXT) on March 18, 2026?

Warrants cover up to 19,750,001 shares with an exercise price of $0.12 and a five-year term. According to the company, warrant exercises could provide additional capital to support long-term growth plans.

How does Bioxytran (BIXT) plan to use the proceeds from the $1.2M financing?

The company intends to use net proceeds for working capital and general corporate purposes, including advancing development programs and supporting selected commercialization efforts. According to the company, funds will support both clinical and near-term commercial activities.

Will Bioxytran (BIXT) launch any products after the March 2026 financing?

Bioxytran expects to introduce A-SUQAR®, a plant-derived dietary supplement, this quarter. According to the company, this near-term commercial initiative complements ongoing advancement of its pharmaceutical programs.

Are the securities from Bioxytran's (BIXT) March 2026 private placement registered for resale?

No, the securities were offered in a private placement and have not been registered under the Securities Act. According to the company, resale requires registration or an applicable exemption from registration requirements.